The convertible note structure introduces potential future dilution if shares trade above $41.66, though the 35% conversion premium provides a meaningful buffer. The debt repayment reduces leverage, but the concurrent stock buyback from note investors may raise governance concerns. Traders should monitor whether the buyback lifts short-term price action and watch for any secondary offering or conversion activity as the stock approaches the conversion threshold.
Price Chart
Executive Summary
Indivior Pharmaceuticals announced the pricing of a $450 million offering of 0.625% convertible senior notes due 2031, upsized from $400 million, with an option for initial purchasers to buy up to an additional $50 million. The company will use net proceeds to repay existing debt, repurchase $75 million of its common stock concurrently, and fund general corporate purposes. The notes are convertible at a premium of 35% to the March 12, 2026 stock price, with a conversion price of $41.66 per share.
Key Financial Metrics
Key Facts
- Indivior priced $450 million in 0.625% convertible senior notes due 2031, with a 30-day option for up to $50 million more.
- Net proceeds estimated at $437.7 million ($486.4 million if option is exercised), after discounts and expenses.
- Company will use ~$239 million to repay and terminate its term loan and revolving credit facility, using additional $102 million in cash on hand.
- Concurrently repurchasing ~$75 million of its common stock (approx. 2.4 million shares) from note purchasers in private transactions.
- Initial conversion price of $41.66 per share, representing a 35% premium to the March 12 closing price.
- Notes are unsecured, senior obligations; convertible under certain conditions, redeemable by Indivior after March 2029 if stock price exceeds 130% of conversion price.
Financial Impact
$450 million raised (up to $500 million with option), $75 million in concurrent share repurchases, $341 million used for debt repayment and buyback
Risk Factors
- Future equity dilution if the stock price rises above the conversion price of $41.66 and notes are converted.
- Concurrent share repurchase from initial note purchasers could be perceived as a circular transaction that benefits underwriters at the expense of long-term shareholders.
- Interest expense and debt service obligations remain, despite refinancing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255228 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | EFFECT | $34.47 $35.53 | ▲ +3.08% | ▲ +2.97% | $35.71 (+3.60%) |
Aug 28, 2026 4w ago | S-4 | $34.93 $34.32 | ▼ −1.75% | ▼ −1.60% | $35.71 (+2.23%) |
Aug 3, 2026 8w ago | 425 / 8-K | $37.37 $38.47 | ▲ +2.94% | ▲ +0.92% | $35.71 (−4.44%) |
Aug 3, 2026 8w ago | 425 | $37.37 $38.47 | ▲ +2.94% | ▲ +0.92% | $35.71 (−4.44%) |
Aug 3, 2026 8w ago | 8-K | $37.37 $38.47 | ▲ +2.94% | ▲ +0.92% | $35.71 (−4.44%) |
Aug 3, 2026 8w ago | 425 / 8-K | $37.37 $38.47 | ▲ +2.94% | ▲ +0.92% | $35.71 (−4.44%) |
Jul 23, 2026 10w ago | Press Release | $40.51 $40.22 | ▼ −0.72% | ▼ −1.19% | $35.71 (−11.85%) |
Jun 12, 2026 16w ago | Insider Cluster | $38.40 $38.32 | ▼ −0.21% | ▲ +1.17% | $35.71 (−7.01%) |
May 15, 2026 20w ago | 8-K | $36.54 $37.81 | ▲ +3.48% | ▲ +1.86% | $35.71 (−2.27%) |
May 4, 2026 21w ago | 8-K | $38.98 $38.84 | ▼ −0.36% | ▼ −3.30% | $35.71 (−8.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access